Chronic oral administration of ibrutinib prevents long-term memory deficits and reduces AD pathology and neuroinflammatory responses in a mouse model of AD

Abstract We previously demonstrated that ibrutinib has therapeutic efficacy against AD pathologies when injected intraperitoneally at a lower dosage (10 mg/kg, daily for 2 weeks) or orally at a higher dosage (30 mg/kg, daily for 1 month) in AD mice models. However, the effect of chronic lower dose o...

Full description

Saved in:
Bibliographic Details
Main Authors: Hyun-ju Lee, Sora Kang, Yoo Joo Jeong, Jin-Hee Park, Jeong-Woo Hwang, Chan-Hu Gu, Tae-Mi Jung, Seokjun Oh, Ji-Yeong Jang, Hyang-Sook Hoe
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Molecular Brain
Subjects:
Online Access:https://doi.org/10.1186/s13041-025-01225-7
Tags: Add Tag
No Tags, Be the first to tag this record!